Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 25,482 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 25,482 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the transaction, the insider now directly owns 135,974 shares of the company’s stock, valued at approximately $2,043,689.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Mineralys Therapeutics Stock Down 0.8 %

MLYS stock opened at $14.04 on Friday. The stock’s 50 day moving average price is $12.90 and its 200 day moving average price is $12.60. Mineralys Therapeutics, Inc. has a 1 year low of $5.85 and a 1 year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same period in the previous year, the firm posted ($0.31) earnings per share. On average, research analysts expect that Mineralys Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Thursday, October 31st.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MLYS. SG Americas Securities LLC acquired a new position in Mineralys Therapeutics in the 3rd quarter valued at $110,000. China Universal Asset Management Co. Ltd. lifted its position in Mineralys Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock worth $116,000 after buying an additional 3,732 shares during the period. Bellevue Group AG acquired a new stake in Mineralys Therapeutics in the 1st quarter worth about $119,000. Federated Hermes Inc. grew its holdings in Mineralys Therapeutics by 100.0% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $140,000 after buying an additional 6,000 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Mineralys Therapeutics during the 2nd quarter valued at about $145,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.